Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic...
26 KB (2,420 words) - 02:40, 26 September 2024
drug cetuximab. They discovered that these individuals had IgE antibodies in their blood that were specifically targeted to the portion of cetuximab which...
36 KB (4,036 words) - 18:58, 21 September 2024
the United States in December 2022 for lung cancer and together with Cetuximab in 2024 for colorectal cancer. Adagrasib is indicated for the treatment...
12 KB (751 words) - 20:10, 9 September 2024
Panitumumab (section Panitumumab vs. cetuximab)
the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include...
16 KB (1,421 words) - 15:40, 14 July 2024
infiltrative disorders such as sarcoidosis. Cetuximab is the first-line therapy for Ménétrier disease. Cetuximab is a monoclonal antibody against epidermal...
10 KB (1,084 words) - 22:07, 15 September 2024
was predictive of a very poor response to panitumumab (Vectibix) and cetuximab (Erbitux) therapy in colorectal cancer. As of 2008, the most reliable...
45 KB (5,079 words) - 06:39, 25 June 2024
Allergic Facial nerve palsy Anti-cancer treatments such as erlotinib, cetuximab, and panitumumab, which block the function of EGFR (the epidermal growth...
3 KB (220 words) - 20:32, 27 August 2024
FOLFIRI is often[citation needed] combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate. In the short term...
4 KB (411 words) - 21:05, 6 May 2024
EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab. Brigatinib is an inhibitor of ALK and mutated EGFR. ALK...
10 KB (796 words) - 12:29, 5 August 2024
MAbs approved by the FDA for cancer include: Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab...
49 KB (4,964 words) - 09:59, 20 September 2024
ErbB2) receptor expressed in some types of breast cancer Alemtuzumab Cetuximab target the epidermal growth factor receptor (EGFR). It is approved for...
20 KB (2,234 words) - 01:21, 22 July 2024
advanced NSCLC, a combined chemotherapy treatment approach that includes cetuximab, an antibody that targets the EGFR signalling pathway, is more effective...
51 KB (5,333 words) - 22:13, 7 September 2024
Cutsem E, et al. (January 2015). "Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type...
8 KB (767 words) - 09:34, 21 September 2024
associated with medications such as sulfadoxine-pyrimethamine, ribavirin, cetuximab, and interleukin-4 [1,8-15]. One series of 300 patients with Grover's...
8 KB (770 words) - 22:06, 22 March 2024
non-primate mammals, alpha-gal is also found in cat dander and in the drug cetuximab. Allergic reactions to alpha-gal usually occur 3–6 hours after consuming...
18 KB (2,190 words) - 14:51, 28 September 2024
Dalesio O, Punt CJ (February 2009). "Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer". N Engl J Med. 360 (6): 563–72. doi:10...
23 KB (634 words) - 23:47, 16 August 2024
Passive antibody therapy (section Cetuximab)
of these problems and were suitable for the clinical cancer treatment. Cetuximab (trade name: Erbitux ) is a recombinant chimeric monoclonal antibody designed...
27 KB (2,923 words) - 15:03, 4 April 2024
origin of the tumor cells. Various targeted agents, such as imatinib, cetuximab, gefitinib, trastuzumab, had been used for exploring new treatment for...
19 KB (1,998 words) - 07:13, 6 May 2024
VTX-2337 is a selective TLR-8 agonist and together with monoclonal antibody cetuximab it was used as a potential therapy for the treatment of recurrent or metastatic...
75 KB (9,227 words) - 03:58, 24 August 2024
advantage at three years was noted when cetuximab was given concurrently with radiation (bioradiation). Cetuximab trials were completed prior to knowledge...
233 KB (24,397 words) - 10:16, 16 July 2024
currently used conventional antibodies like trastuzumab (targeting HER2/neu), cetuximab and panitumumab (both targeting the EGF receptor), using the BiTE approach...
9 KB (1,472 words) - 21:30, 9 September 2024
of a drug depends on the genotype of a patient. For example, Erbitux (cetuximab) increases the survival rate of colorectal cancer patients if they carry...
33 KB (3,391 words) - 18:28, 6 September 2024
implicated HER2 signaling in resistance to the EGFR-targeted cancer drug cetuximab. The high expression of HER2 correlates with better survival in esophageal...
43 KB (4,651 words) - 13:41, 27 July 2024
therapies used in head and neck cancers include cetuximab, bevacizumab, and erlotinib.[citation needed] Cetuximab is used for treating people with advanced-stage...
105 KB (11,717 words) - 15:12, 25 September 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
92 KB (8,688 words) - 04:50, 27 September 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
31 KB (3,430 words) - 05:24, 28 August 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
68 KB (5,999 words) - 20:41, 31 August 2024
marketed product is Erbitux (cetuximab), for which it has marketing rights worldwide, apart from North America. (Cetuximab was discovered by Imclone Systems...
48 KB (4,734 words) - 01:32, 27 September 2024
trial sought to compare the efficacy of Abituzumab, cetuximab, and irinotecan compared to cetuximab and irinotecan in patients with KRAS (exon 2) wild-type...
9 KB (974 words) - 19:52, 20 December 2023
At ImClone, Waksal led the company to develop the cancer drug Erbitux (cetuximab). During the course of its review process with the Food and Drug Administration...
17 KB (1,400 words) - 22:21, 10 September 2024